{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:13:43Z","timestamp":1766182423166,"version":"3.48.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jve.2025.100611","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:18:47Z","timestamp":1759547927000},"page":"100611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A liberalized approach to directly observed therapy for HCV retains excellent cure rates among PWID in Vienna"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7762-7483","authenticated-orcid":false,"given":"Caroline","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Anibas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David JM.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Burghart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enisa","family":"Gutic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jve.2025.100611_bib2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/hep.27377","article-title":"Hepatitis C virus: the 25-year journey from discovery to cure","volume":"60","author":"Ward","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jve.2025.100611_bib3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep.30303","article-title":"Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States","volume":"69","author":"Park","year":"2019","journal-title":"Hepatol Baltim Md"},{"issue":"11","key":"10.1016\/j.jve.2025.100611_bib4","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"21","key":"10.1016\/j.jve.2025.100611_bib5","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"15","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jve.2025.100611_bib6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"issue":"10178","key":"10.1016\/j.jve.2025.100611_bib7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.jve.2025.100611_bib8","first-page":"456","article-title":"Progress towards hepatitis C virus elimination in high-income countries: an updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"5","key":"10.1016\/j.jve.2025.100611_bib9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Clinical practice guidelines panel: chair:, EASL governing board representative:, panel members: EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"issue":"9\u201310","key":"10.1016\/j.jve.2025.100611_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00508-020-01790-y","article-title":"Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence","volume":"133","author":"Steininger","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jve.2025.100611_bib12","article-title":"HCV hotline facilitates hepatitis C elimination during the COVID-19 pandemic","volume":"5","author":"Hartl","year":"2022","journal-title":"J Viral Hepat"},{"issue":"29","key":"10.1016\/j.jve.2025.100611_bib13","article-title":"ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria","author":"Schwarz","year":"2023","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S2468-1253(20)30366-6","article-title":"The phases of hepatitis C elimination: achieving WHO elimination targets","volume":"6","author":"Pedrana","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jve.2025.100611_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","article-title":"Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore","volume":"100","author":"Falade-Nwulia","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.jve.2025.100611_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102766","article-title":"\u201cEverybody living with a chronic disease is entitled to be cured\u201d: challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs","volume":"81","author":"Goodyear","year":"2020","journal-title":"Int J Drug Pol"},{"issue":"2","key":"10.1016\/j.jve.2025.100611_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/add.13197","article-title":"Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS study","volume":"111","author":"Grebely","year":"2016","journal-title":"Addict Abingdon Engl"},{"issue":"8","key":"10.1016\/j.jve.2025.100611_bib18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/v16081304","article-title":"Distrust in the health care system and adherence to direct-acting antiviral therapy among people with hepatitis C virus who inject drugs","volume":"16","author":"Padi","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"\u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York city","volume":"17","author":"Muncan","year":"2020","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12879-024-09124-3","article-title":"Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study","volume":"24","author":"Lopes","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.jve.2025.100611_bib21","article-title":"CHIME - a tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers","volume":"9","author":"Schwarz","year":"2023","journal-title":"J Virus Erad"},{"issue":"3","key":"10.1016\/j.jve.2025.100611_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229239","article-title":"Directly observed therapy for HCV with glecaprevir\/pibrentasvir alongside opioid substitution in people who inject drugs-first real world data from Austria","volume":"15","author":"Schmidbauer","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jve.2025.100611_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252274","article-title":"Directly observed therapy at opioid substitution facilities using sofosbuvir\/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy","volume":"16","author":"Schmidbauer","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib24","article-title":"Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy","volume":"9","author":"Schwarz","year":"2023","journal-title":"J Virus Erad"},{"issue":"2","key":"10.1016\/j.jve.2025.100611_bib25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pnpbp.2010.12.002","article-title":"Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance","volume":"35","author":"Gerra","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.jve.2025.100611_bib26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jvh.13175","article-title":"Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection","volume":"26","author":"Read","year":"2019","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jve.2025.100611_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2055-6640(20)30255-7","article-title":"Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis","volume":"4","author":"McDermott","year":"2018","journal-title":"J Virus Erad"},{"year":"2017","series-title":"\u00d6sterreichische Gesellschaft f\u00fcr Allgemein- und Familienmedizin (\u00d6GAM), \u00d6sterreichische Gesellschaft f\u00fcr Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (\u00d6GKJP), \u00d6sterreichische Gesellschaft f\u00fcr Psychiatrie und Psychotherapie (\u00d6GPP)","key":"10.1016\/j.jve.2025.100611_bib28"},{"issue":"Supplement_5","key":"10.1016\/j.jve.2025.100611_bib29","doi-asserted-by":"crossref","first-page":"v5","DOI":"10.1093\/jac\/dkz451","article-title":"The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK","volume":"74","author":"Ward","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.jve.2025.100611_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016153","article-title":"Ability to join the workforce and work productivity among drug users under methadone maintenance treatment in a mountainous area of Northern Vietnam: a cross-sectional study","volume":"7","author":"Nong","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jve.2025.100611_bib33","first-page":"381","article-title":"New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension","volume":"35","author":"Schwabl","year":"2015","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"3\u20134","key":"10.1016\/j.jve.2025.100611_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00508-017-1231-x","article-title":"Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV\/HCV coinfected patients","volume":"130","author":"Chromy","year":"2018","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/hiv.12082","article-title":"Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV\/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration","volume":"15","author":"Castera","year":"2014","journal-title":"HIV Med"},{"issue":"9","key":"10.1016\/j.jve.2025.100611_bib36","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.sapharm.2019.04.004","article-title":"Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: a qualitative study","volume":"16","author":"Gunn","year":"2020","journal-title":"Res Soc Adm Pharm RSAP"},{"key":"10.1016\/j.jve.2025.100611_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","article-title":"DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy","volume":"47","author":"Radley","year":"2017","journal-title":"Int J Drug Pol"},{"year":"2024","series-title":"World Drug Report 2024","key":"10.1016\/j.jve.2025.100611_bib38"},{"year":"2024","series-title":"European Drug Report","key":"10.1016\/j.jve.2025.100611_bib39"},{"issue":"8","key":"10.1016\/j.jve.2025.100611_bib40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/jvh.13701","article-title":"Randomized clinical trial: direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection","volume":"29","author":"Beer","year":"2022","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.jve.2025.100611_bib41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2023.12.020","article-title":"Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: the HERO study","volume":"80","author":"Heo","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jve.2025.100611_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa377","article-title":"Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents","volume":"7","author":"Norton","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jve.2025.100611_bib43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/a-2313-0111","article-title":"Adherence in hepatitis C virus treatment: what we know","volume":"44","author":"Flamm","year":"2024","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.arcmed.2020.09.012","article-title":"Subsequent curves of COVID-19 in society","volume":"52","author":"Ramos-Z\u00fa\u00f1iga","year":"2021","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jve.2025.100611_bib45","doi-asserted-by":"crossref","DOI":"10.2196\/65204","article-title":"Economic deterioration and social factors affecting mental health during the COVID-19 pandemic in Japan: web-based cross-sectional survey","volume":"9","author":"Hori","year":"2025","journal-title":"JMIR Form Res"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2021.10.022","article-title":"The COVID-19 pandemic","volume":"128","author":"Abrams","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12954-021-00519-y","article-title":"Therapy of chronic hepatitis C in people who inject drugs: focus on adherence","volume":"18","author":"Frankova","year":"2021","journal-title":"Harm Reduct J"},{"issue":"7","key":"10.1016\/j.jve.2025.100611_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083502","article-title":"Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (the QuickStart study): a cluster randomised cross-over trial protocol","volume":"14","author":"Doyle","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12954-024-01136-1","article-title":"Practical solutions to resolve social barriers to hepatitis C treatment initiation among people who inject drugs: a qualitative study","volume":"21","author":"Aung","year":"2024","journal-title":"Harm Reduct J"},{"issue":"11","key":"10.1016\/j.jve.2025.100611_bib51","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3390\/v16111792","article-title":"Elimination of HCV infection: recent epidemiological findings, barriers, and strategies for the coming years","volume":"16","author":"Torre","year":"2024","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.jve.2025.100611_bib53","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jvh.12852","article-title":"Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia","volume":"25","author":"Hajarizadeh","year":"2018","journal-title":"J Viral Hepat"},{"issue":"9","key":"10.1016\/j.jve.2025.100611_bib54","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/cid\/ciz546","article-title":"Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs","volume":"70","author":"Wade","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"8","key":"10.1016\/j.jve.2025.100611_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.30024","article-title":"Hepatitis C virus reinfection among people who inject drugs: long-term Follow-Up of the HERO study","volume":"7","author":"Litwin","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jve.2025.100611_bib56","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1186\/s12889-024-20625-3","article-title":"Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study","volume":"24","author":"Chac\u00f3n","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jve.2025.100611_bib57","article-title":"Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy","author":"M","year":"2024","journal-title":"Infection"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664025000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664025000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:07:41Z","timestamp":1766182061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664025000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2055664025000305"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2025.100611","relation":{},"ISSN":["2055-6640"],"issn-type":[{"type":"print","value":"2055-6640"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A liberalized approach to directly observed therapy for HCV retains excellent cure rates among PWID in Vienna","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2025.100611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100611"}}